GLP-1 Drug Decision Quiz

Four questions. Output: the FDA-approved GLP-1 medication (or two) that best matches your profile, with the underlying trial evidence cited at every branch — STEP, SURMOUNT, SELECT, FLOW, STEP-HFpEF, SURMOUNT-OSA, or STEP-TEENS — plus a link to the relevant Weight Loss Rankings provider ranking.

This decision support is part of Weight Loss Rankings' living editorial database — 100+ research articles and 158+ clinically-reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

Not medical advice. This tool produces patient-facing decision support based on FDA-approved indications and outcomes-trial evidence. The final medication choice must be made with your prescribing clinician based on your full medical history.
1234

Step 1 of 4 — What is your current BMI range?

If you don't know your BMI, use our BMI calculator first. The FDA approves Wegovy, Zepbound, Saxenda, and Foundayo for chronic weight management at BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity.

Need to calculate? Use the BMI calculator →

How the recommendation logic works

The decision tree is rule-based, not AI-inferred. Every branch traces to either an FDA-approved indication on a specific drug label (Section 1: Indication and Usage) or an outcomes-trial finding from the published clinical literature.

  • BMI eligibility — FDA labels for Wegovy, Zepbound, Saxenda, and Foundayo all state BMI ≥30 OR BMI ≥27 with at least one weight-related comorbidity.
  • Type 2 diabetes path — Mounjaro, Ozempic, and Rybelsus are FDA-approved for T2D. The SURPASS-2 head-to-head supports tirzepatide over semaglutide on HbA1c reduction.
  • Established CV disease — SELECT (Lincoff et al, NEJM 2023, PMID 37952131) showed semaglutide 2.4 mg reduced major adverse cardiovascular events 20% (HR 0.80, 95% CI 0.72-0.90) in 17,604 non-diabetic adults with overweight/obesity and CV disease. Wegovy is preferred for this profile.
  • HFpEF — STEP-HFpEF supports semaglutide for symptom and exercise-capacity improvement.
  • T2D + CKD — FLOW trial (NEJM 2024) showed semaglutide 1 mg reduced the composite kidney outcome 24% (HR 0.76, 95% CI 0.66-0.87) in T2D + CKD. Ozempic is preferred for this profile.
  • Obstructive sleep apnea — SURMOUNT-OSA showed tirzepatide reduced apnea-hypopnea index by approximately 50% in OSA + obesity. Zepbound is the only GLP-1 with dedicated OSA trial evidence.
  • Adolescent (12-17) — Wegovy is the FDA-approved option, supported by STEP-TEENS (Weghuber et al, NEJM 2022). Tirzepatide and orforglipron are not currently approved in this age range.
  • Stop conditions — pregnancy or active planning, breastfeeding, personal/family history of MTC or MEN-2: every FDA GLP-1 label contraindicates treatment in these populations.

Related research and tools

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  4. 4.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  5. 5.Novo Nordisk Inc. RYBELSUS (semaglutide) tablets — US Prescribing Information, Section 1: Indication and Usage (type 2 diabetes). FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  6. 6.Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  7. 7.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, Section 1: Indication and Usage. FDA Approved Labeling — DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  8. 8.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
  9. 9.Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  10. 10.Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.